Compare FSI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | ENTX |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 74.7M |
| IPO Year | 2000 | 2015 |
| Metric | FSI | ENTX |
|---|---|---|
| Price | $5.56 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 15.4K | ★ 93.3K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | 0.09 | ★ 0.18 |
| Revenue | ★ $15,494,325.00 | $181,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $58.09 | N/A |
| P/E Ratio | $61.78 | ★ $7.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $1.00 |
| 52 Week High | $11.48 | $3.22 |
| Indicator | FSI | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 50.25 |
| Support Level | $5.48 | $1.17 |
| Resistance Level | $6.08 | $1.61 |
| Average True Range (ATR) | 0.21 | 0.15 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 38.81 | 57.38 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.